Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

The study will enroll patients with moderate to severe plaque psoriasis. Patient enrolment will be initiated in Europe and US and Canada expected to follow. The study is a randomized, double-blind, ...

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

The price you pay for Ilumya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

Filling an empty space on the wall of presidential portraits in the Colorado Capitol with a new painting of Donald Trump ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

The following is a summary of “Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1,” published in the March 2025 issue of ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...